Intravascular hemolysis following low dose daily rifampin.
We report two pediatric patients with rifampin-induced hemolysis following treatment with low daily dose rifampin for methicillin-resistant Staphylococcus aureus (MRSA). With the increased use of rifampin to treat MRSA, physicians should be aware that patients receiving rifampin therapy are at risk for hemolysis, even at low daily doses.
Neunert
Cindy E
CE
Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390-9063, USA. cindy.neunert@utsouthwestern.edu
Paranjape
Geeta S
GS
Cameron
Scott
S
Rogers
Zora R
ZR
D000293:Adolescent; D000743:Anemia, Hemolytic / Q000209:etiology*; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D006461:Hemolysis / Q000187:drug effects*; D006801:Humans; D007223:Infant; D008297:Male; D016106:Methicillin Resistance; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects*; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects*; D013203:Staphylococcal Infections / Q000188:drug therapy*
D000904:Antibiotics, Antitubercular; D012293:Rifampin